Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Change in dietary behaviour |
Through the Mediterranean Diet Adherence Screener (14 items food questionnaire, MEDAS) questionnaire, with a minimum score of 0 and a maximum of 14. A higher score indicates a higher diet quality which is a better outcome |
Screening and 3 months upon the completion |
|
Other |
Change in plasma insulin |
Measured using ELISA |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Other |
Change in plasma glucose |
Measured by autoanalyser |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Other |
Change in plasma triglycerides |
Measured by autoanalyser |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Other |
Change in plasma cortisol |
Measured by autoanalyser |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Other |
Change in plasma brain derived neurotropic factor |
Measured by ELISA |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Other |
Change in plasma serotonin |
Measured by ELISA |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Primary |
Change in mood |
Established by the Bond-Lader visual analogue scale (includes 16 items each having antonyms on two ends, on a scale of 1 to 100, 50 being the neutral point) |
Baseline (morning of day 1), Postprandial (after lunch on Established by the Bond-Lader visual analogue scale (includes 16 items each having day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Primary |
Change in anxiety |
Established by the Profile of Mood States (includes 65 items on a 5 point Likert scale) |
Baseline (morning of day 1), Postprandial (after lunch on day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Secondary |
Change in cognitive performance |
Established by a neuropsychological test battery (https://neuropsychology.online) which assesses the following measures; attention, motor function, executive function, episodic memory, impulse control, visuospatial function |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Secondary |
Cerebral blood flow |
Measured using MRI |
Postprandial day 1 |
|
Secondary |
Change in blood pressure |
Measurements of brachial artery blood pressure (both diastolic and systolic pressure) |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Secondary |
Change in gut microbiota speciation |
Faecal samples will be analysed for the gut microflora using 16sRNA sequencing. |
Baseline (morning of day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Secondary |
Change in plasma short chain fatty acids (SCFA) |
Acetate, propionate and butyrate |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Secondary |
Change in untargeted metabolomics |
Analysed through faecal samples using 1H-NMR-based untargeted metabolomics approach. |
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention) |
|
Secondary |
Habitual sleep quality profile assessed by the Pittsburgh Sleep Quality Index |
The Pittsburgh Sleep Quality Index is a 10-items validated questionnaire, which is based on 'the last month'. It will be used to establish usual sleep habits (before the interventions) and to identify sleep disturbances if there is any. |
Baseline (morning of day 1) |
|
Secondary |
Change in subjective sleep quantity |
Assessed using the Karolinska Sleep Diary (KSD). The KSD is a series of questions, with 5 possible tick box options, which characterise the efficiency and the duration of last night's sleep. |
Each morning, days 1-6 |
|
Secondary |
Change in subjective sleep quality |
Assessed using the Karolinska Sleepiness Scale (KSS). The KSS is a single item, 9-point scale, assessing the sleepiness level at a particular time of day. |
Each morning, days 1-6 |
|
Secondary |
Change in objective sleep quality |
Assessed using the MotionWatch 8. The MotionWatch 8 is a medical-grade actigraphy watch which can be used to monitor sleep, circadian rhythm and physical activity. Its software (The Motion Ware) will provide two objective measures of sleep quality, namely sleep efficiency and sleep fragmentation. |
Each morning, days 1-6 |
|
Secondary |
APOE4 genotype status |
Assessed through DNA genotyping |
Baseline (day 1) |
|
Secondary |
Participants subjective overview of the intervention |
Assessed through a non-validated single question |
Upon completion of 5 full days |
|